title: Chemopreventive effects of anastrozole in a premenopausal breast cancer model.
abstract: BACKGROUND
  Monotherapy with aromatase inhibitors has no established role in premenopausal breast cancer in women and is an area of future exploration.
  
  
  METHODS
  In this study, chemopreventive effects of anastrozole in the model of N-methyl-N-nitrosourea-induced premenopausal mammary carcinogenesis in female rats were evaluated. Anastrozole was dietarily administered at two concentrations: 0.05 mg/kg (ANA 0.05) and 0.5 mg/kg (ANA 0.5). Basic parameters of experimental carcinogenesis and side-effects on selected organs after anastrozole treatment in animals were assessed.
  
  
  RESULTS
  In the ANA 0.5 group, anastrozole suppressed tumor incidence by 40% (p<0.05) and tumor frequency by 57% (p<0.01), as well as lengthening the latency period by 10 days (p=0.084) compared to control animals. Adverse effects of anastrozole on the genital system (uterus and vagina) and lipid and bone metabolism in rats were not found. Anastrozole did not alter serum concentrations of estradiol, testosterone or dehydroepiandrosterone in animals. An increase in the body weight gain of rats in the ANA 0.5 group compared with the controls (p<0.01) was observed.
  
  
  CONCLUSIONS
  This study is the first about the antineoplastic effects of anastrozole in a model of premenopausal mammary carcinogenesis in female rats.
authors.affiliation: Department of Pharmacology, Jessenius Faculty of Medicine, Comenius University, Sklabinská 26, 037 53 Martin, Slovak Republic. kubatka@jfmed.uniba.sk
authors.forename: Peter
authors.initials: P
authors.lastname: Kubatka
authors.forename: Vladimíra
authors.initials: V
authors.lastname: Sadlonová
authors.forename: Karol
authors.initials: K
authors.lastname: Kajo
authors.forename: Gabriela
authors.initials: G
authors.lastname: Nosál'ová
authors.forename: Daniela
authors.initials: D
authors.lastname: Ostatníková
authors.forename: Katarína
authors.initials: K
authors.lastname: Adamicová
mesh_terms: D000077384:Anastrozole; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000633:toxicity; D003687:Dehydroepiandrosterone / Q000097:blood; D004032:Diet; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D008770:Methylnitrosourea; D009570:Nitriles / Q000008:administration & dosage* / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D013739:Testosterone / Q000097:blood; D014230:Triazoles / Q000008:administration & dosage* / Q000633:toxicity
chemical_list: D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole; D013739:Testosterone; D003687:Dehydroepiandrosterone; D004958:Estradiol; D008770:Methylnitrosourea